Endocrine Abstracts

Low concentrations of vitamin D leads to secondary hiperparathyroidism, bone loss, and an increase of osteoporotic fractures in populations at risk. Adequate vitamin D and calcium intake is considered an essential component of postmenopausal osteoporosis management. Several epidemiological studies have assessed the prevalence of low serum vitamin D concentrations, indicating that vitamin D inadequacy (<30 ng/ml) is a problem world-wide.Aims: To evalu...

Background and aims: Primary hyperparathyroidism (PHPT) often presents without classical symptoms such as overt skeletal disease or nephrolithiasis. Treatment strategies have been widely discussed. The objective of our research was to study the effect of parathyroidectomy (PTX) compared to observation (OBS) on skeletal outcomes such as bone mineral density (BMD).Subjects and methods: A retrospective observational study was conducted between 1991 and 2014...

Background and aims: Primary hyperparathyroidism (PHPT) is a common endocrine disorder with different epidemiological patterns among countries. The incidence of PHPT is unknown in Spain. The aim of our study is to assess the prevalence and incidence of diagnosed PHPT in adults between 1970 and 2014 in Santander, a population of 290.000 inhabitants, located in the north of Spain.Subjects and methods: All patients diagnosed with primary hyperparathyroidism...

Context: Postmenopausal osteoporosis (PMO) is associated with other comorbidities such as cardiovascular disease and impaired glucose homeostasis. Vitamin D insufficiency is highly prevalent, and may be a common link between these disorders. Recently, it has been shown that vitamin D may be involved in insulin resistance; however, this relationship has not been well evaluated in women with PMO.Objective: To assess the relationship between circulating lev...

Objective: To evaluate the efficacy of dapagliflozin for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with tipo 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and dapagliflozin is added. Variables analyzed baseline and at 6 months after treatme...

Objective: To evaluate the efficacy of canagliflozin 100 mg for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with type 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and canagliflozin 100 mg is added. Variables analyzed baseline and at 6 months...

Objetive: The change of treatment of liraglutide 1.8 mg to dapagliflozin or canaglifonzin 100 mg in patients with optimal glycemic control and stabilization weight loss, achieves progression in weight loss and improves the metabolic control of the patient with tipo 2 diabetes (DM-2). Our objective is to evaluate if there are differences in metabolic control and progression of weight loss in patients treated with canagliflozin 100 mg or dapagliflozin.Pati...

Introduction: Obesity is a major health problem and a risk factor for the development of other diseases. However, there are morbid obese subjects of long evolution that can be considered metabolically healthy obese, whose existence is in doubt for many clinicians.Objetive: To analyze if there are differences in cardiovascular risk between metabolically healthy (MHO) and sick obese (MSO), matched by age, sex and body mass index (BMI).<p class="abstext...

We presented the case of a 21 years old patient, derived from Primary Care to evaluate low testosterone levels (total testosterone (TT) 0.44 ng/ml). His father had delayed pubety and his mother menarche was at 11 years. No other personal history of interest. He had adequate child development and vaccination. No parotiditis. He referred some morning erections. Weight 59 kg, size 171 cm and BMI 20.17 kg/m2. Testes volume (TV) of 4-5 cc, scanty pubic hair. Tanner stage...

Introduction: Hypokalemic periodic paralysis (HPP) belongs to a group of inherited diseases called channelopathies, whose main manifestation include painless muscle paralysis. There are also acquired forms of HPP secondary to hyperthyroidism, called thyrotoxic periodic paralysis (TPP). It’s prevalence is markedly higher in men.Case Reports: Case 1. 34-year-old Venenzuelan man, without medical history. He consults in the emergency de...